STOCK TITAN

Investor group (NASDAQ: VVOS) funds Vivos with $2.39M PIPE and warrants

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

V-CO Investors LLC, related investment entities, and Michael C. Skaff filed a Schedule 13D disclosing a significant stake in Vivos Therapeutics, Inc.. Through V-CO, V-Co 2, and V-Co 3, they directly hold a total of 2,696,123 common shares, representing 19.9% of the company’s common stock.

On March 31, 2026, V-Co 3 entered a private placement with Vivos, purchasing 1,353,625 shares of common stock at $1.34 per share as part of a $2.39 million subscription. V-Co 3 also received Series A and Series B warrants, each exercisable for up to 1,783,582 shares at $1.09 per share, and a pre-funded warrant for up to 429,957 shares at $0.0001 per share, all subject to a 19.99% ownership cap. The filing states the investment is for general working capital and that the investors’ purpose is primarily investment, while reserving the right to discuss strategy and governance with the company.

Positive

  • None.

Negative

  • None.

Insights

Investor group takes a 19.9% stake in Vivos via a structured PIPE.

The filing shows V-CO entities and related manager SP Manager LLC, led by Michael C. Skaff, collectively beneficially owning 2,696,123 Vivos shares, or 19.9% of common stock, based on 12,132,381 shares outstanding plus new PIPE shares as of March 31, 2026.

On that date, V-Co 3 invested $2,390,000 in a private placement, including conversion of a $1,400,000 Convertible Promissory Note with a $140,000 original issue discount. The deal combined common stock at $1.34 per share with Series A and B warrants at $1.09 and a pre-funded warrant at $0.0001, all immediately exercisable.

A 19.99% blocker provision limits warrant and pre-funded warrant exercises so the group cannot exceed that ownership threshold. The filing states the purpose is investment and potential dialogue on performance, strategy, and governance, while explicitly listing no current plans for control transactions. Future company disclosures may clarify how actively this investor group engages with management.

Subscription Amount $2,390,000 Total funds for March 31, 2026 private placement
Common shares bought by V-Co 3 1,353,625 shares at $1.34 PIPE Common Stock purchased March 31, 2026
Series A Warrant size 1,783,582 shares at $1.09 Immediately exercisable, two-year term
Series B Warrant size 1,783,582 shares at $1.09 Immediately exercisable, five-year term
Pre-Funded Warrant size 429,957 shares at $0.0001 Immediately exercisable pre-funded warrant
Group beneficial ownership 2,696,123 shares (19.9%) Shares attributed to SP Manager LLC and Michael C. Skaff
Shares outstanding baseline 12,132,381 shares Common Stock outstanding as of March 31, 2026
Ownership blocker threshold 19.99% Cap on exercise of warrants and pre-funded warrant
Schedule 13D regulatory
"If the filing person has previously filed a statement on Schedule 13G to report the acquisition..."
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
Convertible Promissory Note financial
"pursuant to a Convertible Promissory Note, dated January 15, 2026, between the Issuer and V-Co 3"
A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.
original issue discount financial
"The Convertible Promissory Note included an original issue discount of $140,000."
Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.
Pre-Funded Warrant financial
"a Pre-Funded Warrant ("Pre-Funded Warrant") to purchase up to 429,957 shares of Common Stock"
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
blocker provision regulatory
"Each of these are excluded due to a blocker provision under which the holder thereof does not have the right to exercise"
beneficial ownership financial
"Without such blocker provisions, V-CO may be deemed to have beneficial ownership of an additional 5,926,034 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentage is calculated based upon (i) 12,132,381 shares of Common Stock issued and outstanding as of March 31, 2026, as reported by the Issuer, plus (ii) 1,353,625 shares of Common Stock issued to V-Co Investors 3 LLC on March 31, 2026 in connection with a private financing between V-Co Investors 3 LLC and the Company.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentage is calculated based upon (i) 12,132,381 shares of Common Stock issued and outstanding as of March 31, 2026, as reported by the Issuer, plus (ii) 1,353,625 shares of Common Stock issued to V-Co Investors 3 LLC on March 31, 2026 in connection with a private financing between V-Co Investors 3 LLC and the Issuer.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentage is calculated based upon (i) 12,132,381 shares of Common Stock issued and outstanding as of March 31, 2026, as reported by the Issuer, plus (ii) 1,353,625 shares of Common Stock issued to V-Co Investors 3 LLC on March 31, 2026 in connection with a private financing between V-Co Investors 3 LLC and the Issuer.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentage is calculated based upon (i) 12,132,381 shares of Common Stock issued and outstanding as of March 31, 2026, as reported by the Issuer, plus (ii) 1,353,625 shares of Common Stock issued to V-Co Investors 3 LLC on March 31, 2026 in connection with a private financing between V-Co Investors 3 LLC and the Issuer.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentage is calculated based upon (i) 12,132,381 shares of Common Stock issued and outstanding as of March 31, 2026, as reported by the Issuer, plus (ii) 1,353,625 shares of Common Stock issued to V-Co Investors 3 LLC on March 31, 2026 in connection with a private financing between V-Co Investors 3 LLC and the Issuer.


SCHEDULE 13D


V-CO Investors LLC
Signature:Michael C. Skaff
Name/Title:Michael C. Skaff, Managing Director of SP Manager LLC, its Manager
Date:04/02/2026
V-Co Investors 2 LLC
Signature:Michael C. Skaff
Name/Title:Michael C. Skaff, Managing Director of SP Manager LLC, its Manager
Date:04/02/2026
V-Co Investors 3 LLC
Signature:Michael C. Skaff
Name/Title:Michael C. Skaff, Managing Director of SP Manager LLC, its Manager
Date:04/02/2026
SP Manager LLC
Signature:Michael C. Skaff*
Name/Title:Michael C. Skaff, Managing Director
Date:04/02/2026
Michael C. Skaff
Signature:Michael C. Skaff*
Name/Title:Michael C. Skaff, Managing Director
Date:04/02/2026
Comments accompanying signature:
*This Reporting Person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose.

FAQ

What stake in Vivos Therapeutics (VVOS) does the V-CO investor group report?

The investor group led by SP Manager LLC reports beneficial ownership of 2,696,123 Vivos common shares, or 19.9% of the company. This percentage is based on 12,132,381 shares outstanding plus 1,353,625 new shares issued to V-Co 3 in the March 31, 2026 private financing.

How much did V-Co 3 invest in the Vivos Therapeutics (VVOS) private placement?

V-Co 3 committed a total subscription amount of $2,390,000 in the private placement. This sum includes the conversion and full satisfaction of a $1,400,000 Convertible Promissory Note, which carried a $140,000 original issue discount, into equity securities of Vivos Therapeutics.

What securities did V-Co 3 receive from Vivos Therapeutics (VVOS) on March 31, 2026?

V-Co 3 received 1,353,625 common shares, Series A and Series B warrants each for up to 1,783,582 shares at $1.09, and a pre-funded warrant for up to 429,957 shares at $0.0001. All instruments were issued in a private placement for general working capital purposes.

What price did V-Co 3 pay per share in the Vivos Therapeutics (VVOS) PIPE?

V-Co 3 purchased the common shares at $1.34 per share in the private placement. This pricing was described as compliant with Nasdaq listing rules and formed part of the overall $2,390,000 subscription that also included note conversion and warrant issuances.

Is there an ownership cap on the Vivos Therapeutics (VVOS) warrants held by V-Co 3?

Yes. The Series A and B common stock warrants and the pre-funded warrant include a 19.99% blocker provision. This prevents V-Co 3 and its affiliates from exercising these instruments if doing so would push their beneficial ownership above 19.99% of Vivos’s outstanding common stock.

What is the stated purpose of the V-CO group’s investment in Vivos Therapeutics (VVOS)?

The filing states the securities were acquired for investment purposes and general working capital for Vivos. The investors may discuss financial performance, strategic direction, operations, and governance with management, but currently list no concrete plans for mergers, asset sales, or control changes.